Zhengye Biotechnology Holding Limited
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Songlin Song
- Full Time Employees
- 278
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- No.1 Lianmeng Road Jilin People's Republic of China 132101
- IPO Date
- Jan 7, 2025
- CIK
- 0001975641
- Website
- jlzybio.com
- Similar Companies
- Business
- Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines with a primary focus on livestock including swine, cattle, goats, sheep, poultry, and dogs. Its product portfolio comprises approximately 46 veterinary vaccines covering monovalent, polyvalent, combined, and combined and polyvalent vaccines. The company operates three GMP veterinary vaccine production floors with 13 production lines, a quality examination center, and an animal facility dedicated to vaccine development. Zhengye markets its products across 28 provincial regions in China and exports internationally to Vietnam, Pakistan, and Egypt. Founded in 2004 and headquartered in Jilin, China, the company serves livestock farmers, local governments, domestic distributors, and exporting distributors. In the last two years, Zhengye completed a successful Nasdaq initial public offering in January 2025, raising approximately $6.9 million to support expansion. Strategic shifts include reducing reliance on swine vaccines to diversify its customer base and accelerate growth in the pet vaccine segment, marked by completed clinical trials for cat and dog vaccines. The company also received two Category I New Veterinary Drug Certificates from the Ministry of Agriculture and Rural Affairs for vaccines developed jointly with academic and industry partners, granting market exclusivity and reinforcing its R&D capabilities. Zhengye continues to invest in expanding global distribution and manufacturing capacity, positioning itself for growth in both domestic and international veterinary vaccine markets. It operates as a subsidiary of Securingium Holding Limited.
Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results
Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure
Short Interest in Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Declines By 36.7%
Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders
Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results
Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F
Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option
U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline
Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering
Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering
Zhengye Biotechnology's Growth Slows As It Seeks U.S. IPO